Engineered receptors and ultrapotent, FDA-approved agonists enable clinical applications of chemogenetics Novel ion channel-based platform allows targeted cell activation or silencing controlled by low doses of the anti-smoking drug varenicline Redpin leveraging platform to advance pipeline of targeted cell therapies...
Read More
Company advancing novel platform technologies to enable non-invasive, targeted regulation of neuronal cell activity Aiming to address currently intractable neurologic and psychiatric diseases Redpin Therapeutics today announced the appointment of David Bleakman, PhD, as its Chief Scientific Officer (CSO). Founded...
Read More